INOVIO Aims for October FDA Decision on Lead RRP Therapy
Event summary
- INOVIO's Biologics License Application (BLA) for INO-3107 is under accelerated review with a PDUFA target date of October 30, 2026.
- The company announced a collaboration with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for glioblastoma treatment.
- INOVIO reported a net loss of $19.7 million for Q1 2026, with cash runway extending into Q1 2027.
- R&D and G&A expenses decreased year-over-year, reflecting cost discipline.
The big picture
INOVIO is navigating a critical regulatory milestone for its lead asset, INO-3107, while maintaining financial discipline. The company's strategic focus on rare diseases and oncology aligns with broader industry trends toward targeted therapies. The collaboration with Akeso Inc. underscores INOVIO's efforts to expand its pipeline beyond its core HPV-related indications.
What we're watching
- Regulatory Clarity
- Whether the FDA will confirm INO-3107's eligibility for accelerated approval and the implications for its October decision.
- Commercial Readiness
- The pace at which INOVIO can finalize its commercialization plans for INO-3107 ahead of a potential 2026 approval.
- Pipeline Progress
- How the Akeso collaboration advances INOVIO's glioblastoma program and its broader oncology strategy.
Related topics